BMS, Johns Hopkins in Immuno-Oncology Pact
By

By
Bristol-Myers Squibb (BMS) has formed a five-year research collaboration with the Johns Hopkins University to identify mechanisms of response and resistance in patients whose cancer is being treated with checkpoint…

Janssen, Amgen in Pact for Combo Cancer Therapy
By

By
Janssen Biotech, a Johsnon & Johnson company, has entered into a master clinical trial collaboration and supply agreement with Onyx Pharmaceuticals, the wholly owned South San Francisco, California-based subsidiary of…

Janssen in Deal with Artificial Intelligence Firm
By

By
Janssen Pharmaceuticals, a Johnson & Johnson company, has signed an exclusive license agreement with BenevolentAI, a London-based artificial intelligence company, for a series of clinical-stage drug candidates. BenevolentAI acquired a…

Roche Partners to Develop Cancer Drug
By

By
Roche’s subsidiary, Genentech, has formed a collaboration with Halozyme Therapeutics, a San Diego-based oncology-focused biotechnology company, for clinical studies evaluating up to eight different tumor types beginning in 2017. The…

Sanofi Ends Insulin Pact, Forgives $72 Million Debt
By

By
MannKind Corporation, a Valencia, California-based biopharmaceutical company, has entered into an agreement with Sanofi to terminate remaining terms relating to the companies’ previously announced termination of their pact for inhalend…

Perrigo Reviews Rights to MS Drug Royalty Stream
By

By
Perrigo has said it is evaluating strategic alternatives for the rights to the royalty stream from sales of the multiple sclerosis drug, Tysabri (natalizumab), as part of its ongoing business…

Novavax to Cut Workforce by 30%
By

By
Novavax, a Gaithersburg, Maryland-based clinical-stage vaccine company, has announced a restructuring plan that includes an immediate reduction in its workforce of approximately 30%. The company expects to incur one-time restructuring…

Pfizer Expands Vaccine Access
By

By
Pfizer has expanded its humanitarian assistance program to enable broader access to its vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13 – valent, adsorbed]), in emergency settings by offering its…

Mylan Forms Pact for Biosimilar to Roche’s Rituxan
By

By
Mylan has signed a long-term development and commercialization agreement with Mabion, a Konstantynów Łódzki, Poland-based biopharmaceutical company, through its wholly owned subsidiary, Mylan Ireland, which gives Mylan exclusive rights to…

Eagle to Acquire Arsia, Boosts Formulation Capabilities for Biologics, Biobetters
By

By
Eagle Pharmaceuticals, headquartered in Woodcliff Lake, New Jersey, has agreed to acquire Arsia Therapeutics, a Cambridge, Massachusetts-headquartered early-stage biotechnology firm with proprietary viscosity-reducing technology and formulation expertise, in a deal…